Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

1.2%

1 terminated/withdrawn out of 86 trials

Success Rate

98.6%

+12.1% vs industry average

Late-Stage Pipeline

36%

31 trials in Phase 3/4

Results Transparency

11%

8 of 73 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 1
30(37.0%)
Phase 3
23(28.4%)
N/A
10(12.3%)
Phase 2
10(12.3%)
Phase 4
8(9.9%)
81Total
Phase 1(30)
Phase 3(23)
N/A(10)
Phase 2(10)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (86)

Showing 20 of 86 trials
NCT02746380Phase 3Completed

A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Role: lead

NCT01991145Not ApplicableCompleted

Allogeneic UCB Therapy With EPO in Children With CP

Role: collaborator

NCT03738020Not ApplicableCompleted

Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of YVOIRE Classic Versus Restylane in Nasolabial Fold Intradermal Injection

Role: lead

NCT03051087Phase 4Completed

To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

Role: lead

NCT02204163Phase 3Completed

Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome

Role: lead

NCT02661737Completed

Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Volume s

Role: lead

NCT02334358Completed

Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s

Role: lead

NCT02290301Completed

An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin

Role: lead

NCT02340078Not ApplicableCompleted

A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection

Role: lead

NCT02340091Not ApplicableCompleted

A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Classic Plus Versus YVOIRE Classic in Nasolabial Fold Injection

Role: lead

NCT03015909Phase 4Completed

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

Role: lead

NCT03738007Not ApplicableCompleted

Clinical Study to Evaluate the Correction of Facial Wrinkles and Folds and Safety of YVOIRE Volume Versus Perlane in Nasolabial Fold Injection

Role: lead

NCT02119793Not ApplicableCompleted

Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study

Role: lead

NCT01526577Phase 1Completed

Study of LC23-1306 in Healthy Male Subjects

Role: lead

NCT02715908Phase 3Completed

A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)

Role: lead

NCT02831361Phase 3Completed

Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

Role: lead

NCT01650415Phase 2Completed

Erythropoietin Therapy for Children With Cerebral Palsy

Role: collaborator

NCT02892812Phase 1Completed

A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults

Role: lead

NCT00777647Not ApplicableCompleted

Effect of Carbonated Soft Drinks on the Body Weight

Role: collaborator

NCT02126358Phase 3Completed

Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

Role: lead